Table 1 Patient characteristics by HCV genotype
From: Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
Characteristic | HCV genotype | ||||
|---|---|---|---|---|---|
1a (n = 31) | 1b (n = 39) | 2 (n = 30) | 3 (n = 33) | 4 (n = 23) | |
Gender | |||||
Male | 26 (83%) | 20 (51%) | 11 (36%) | 26 (78%) | 17 (85%) |
Female | 5 (27%) | 19 (49%) | 19 (64%) | 7 (22%) | 3 (15%) |
Race | |||||
Italian | 29 (93%) | 38 (97%) | 30 (100%) | 31 (93%) | 13 (65%) |
Others | 2 (7%) | 1 (3%) | 0 | 2 (7%) | 7 (35%) |
No. of patients HIV-1 co-infected receiving HAART (%) | 5 | 1 | 0 | 4 | 4 |
Median HCV viral load (IU/mL log10) in HCV mono-infected pts | 5.66 (range 3.03-6.44) | 5.63 (range 4.2-6.75) | 5.96 (range 3.6-6.84) | 5.38 (range 2.97-6.58) | 5.66 (range 2.40-6.78) |
Median HCV viral load (IU/mL log10) in HCV/HIV co-infected pts | 6.41 (range 4.73-6.77) | 5.95 | 0 | 6.54 (range 6.17-6.86) | 6.45 (range 6.42-6.52) |